A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients
Authors:
- Daniel GeanonDGDaniel Geanon
- Brian LeeBLBrian Lee
- Geoffrey KellyGKGeoffrey Kelly
- Diana HandlerDHDiana Handler
- Bhaskar UpadhyayaBUBhaskar Upadhyaya
- John LeechJLJohn Leech
- Manon HerbinetMHManon Herbinet
- Diane Del ValleDVDiane Del Valle
- Sacha GnjaticSGSacha Gnjatic
- Seunghee Kim-SchulzeSKSeunghee Kim-Schulze
- Miriam MeradMMMiriam Merad
- Adeeb H. RahmanARAdeeb H. Rahman
Preprint
Abstract
Mass cytometry (CyTOF) represents one of the most powerful tools in immune phenotyping, allowing high throughput quantification of over 40 single parameters at single-cell resolution. However, wide deployment of CyTOF-based immune phenotyping studies are limited by complex experimental workflows and the need for specialized CyTOF equipment and technical expertise. Furthermore, differences in cell isolation and enrichment protocols, antibody reagent preparation, sample staining and data acquisition protocols can all introduce technical variation that can potentially confound integrative analyses of large data-sets of samples processed across multiple labs. Here, we describe the validation of a streamlined whole blood CyTOF workflow that addresses many of these challenges and facilitates wider adoption of CyTOF immune monitoring across sites with limited technical expertise or sample-processing resources or equipment. Our workflow utilizes commercially available reagents including the Fluidigm MaxPar Direct Immune Profiling Assay, a dry tube 30-marker immunophenotyping panel, and SmartTube Proteomic Stabilizer, which allows for simple and reliable fixation and cryopreservation of whole blood samples. We validate a workflow that allows for streamlined staining of whole blood samples with minimal processing requirements or expertise at the site of sample collection, followed by shipment to a central CyTOF core facility for batched downstream processing and data acquisition. We further demonstrate the application of this workflow to characterize immune responses in a cohort of hospitalized COVID-19 patients, highlighting key disease-associated changes in immune cell frequency and phenotype.Keywords
All Related Versions
- Published version: Cytometry Part A, 99 (5), 446.
This publication has 21 references indexed in Scilit:
- Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventionsbioRxiv, 2020
- Multi‐site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis systemCytometry Part B: Clinical Cytometry, 2019
- A Modified Injector and Sample Acquisition Protocol Can Improve Data Quality and Reduce Inter‐Instrument Variability of the Helios Mass CytometerCytometry Part A, 2019
- Development of a Comprehensive Antibody Staining Database Using a Standardized Analytics PipelineFrontiers in Immunology, 2019
- Average Overlap Frequency: A simple metric to evaluate staining quality and community identification in high dimensional mass cytometry experimentsJournal of Immunological Methods, 2018
- Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosisJournal of Immunological Methods, 2018
- Mass cytometry panel optimization through the designed distribution of signal interferenceCytometry Part A, 2016
- Stabilization of pre‐optimized multicolor antibody cocktails for flow cytometry applicationsCytometry Part B: Clinical Cytometry, 2016
- Heparin reduces nonspecific eosinophil staining artifacts in mass cytometry experimentsCytometry Part A, 2016
- Clinical recovery from surgery correlates with single-cell immune signaturesScience Translational Medicine, 2014